Drug Target Review2025-09-02T09:00:00
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2026-06-01T07:00:00
Contributor Dr Timothy O’Connor, Drug Target Review
2026-10-07T14:00:00
Sponsored by WuXi AppTec
2024-02-01T12:06:43
Sponsored by Leica Microsystems
2024-01-09T09:30:19
Sponsored by Sartorius
Site powered by Webvision Cloud